VivoSeq
Oncology

Pleural Mesothelioma

39

Pipeline Programs↗

11

Active Trials↗

22

Companies Involved↗

Pleural Mesothelioma is a moderately active landscape with 39 programs across 22 companies. The most active players are Glaxo Dba Glaxosmithkline, Teva, Regeneron. 4 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

57/100

Pipeline Velocity

15/100

Mech. Concentration

14/100

Completion Rate

79/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

G

Glaxo Dba Glaxosmithkline

1 program

Phase 1Teva logo

Teva

1 program

Phase 1Regeneron logo

Regeneron

2 programs

Phase 2S

Shanghai Pharmaceuticals Holding Co., Ltd

1 program

Phase 2S

Summit Therapeutics

1 program

Phase 2M

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

67%

Small molecule

26 of 39 classified programs — the dominant modality here.

33%ALL OTHERSMonoclonal antibody923%Protein / enzyme25%Cell therapy13%Gene therapy13%

Small molecule leads; the ring shows all 39 classified programs, each share of the total. Modality classified for 98% of 41 pipeline programs.

Analysis

Trial Status

27

clinical trials

Completed11 · 41%
Recruiting7 · 26%
Unknown status2 · 7%
Withdrawn2 · 7%
Not yet recruiting2 · 7%
Active, not recruiting2 · 7%
Other1 · 4%

Clinical Trials

Trial Activity

27 trials

The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural Mesothelioma
Recruiting·—·Phase 2·NCT06790082·70 enrolled
Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma
Recruiting·SSun Yat-sen University·Phase 2·NCT05930665·38 enrolled
Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and Chemotherapy
Recruiting·IIntergroupe Francophone de Cancerologie Thoracique·Phase 2·NCT06840834·38 enrolled
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
Recruiting·AstraZeneca logoAstraZeneca·Phase 3·NCT06097728·825 enrolled
Multicenter Single-Arm Study of Ivonescimab (AK112) Combined with Chemotherapy in Pretreated Pleural Mesothelioma
Recruiting·TThe First Hospital of Jilin University·Phase 2·NCT06875076·25 enrolled
NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility Study
Recruiting·UUniversity Hospital, Antwerp·Phase 1/2·NCT07121374·37 enrolled
A Phase 1a/1b Basket Trial of BMS-986504 With Standard-of-Care Therapy For Patients With Select Metastatic MTAP-deleted Solid Tumors
Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT07532902·60 enrolled
Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study)
Active, not recruiting·IIstituto Oncologico Veneto IRCCS·Phase 2·NCT06155279·41 enrolled
Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma
Active, not recruiting·National Cancer Institute (NCI)·Phase 1/2·NCT03126630·49 enrolled
Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural Mesothelioma
Not yet recruiting·IIntergroupe Francophone de Cancerologie Thoracique·Phase 2·NCT07234058·126 enrolled
Study of Cadonilimab Combined With Chemotherapy in Recurrent / Refractory Pleural Mesothelioma
Not yet recruiting·—·Phase 2·NCT06416930·59 enrolled
Phase II Trial of Neo-Adjuvant Pemetrexed Plus Cisplatin Followed by Surgery and Radiation for Pleural Mesothelioma
Completed·Eli Lilly logoEli Lilly·Phase 2·NCT00087698·77 enrolled
Nivolumab With Chemotherapy in Pleural Mesothelioma After Surgery
Completed·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Phase 2·NCT04177953·92 enrolled
DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma
Completed·PrECOG, LLC.·Phase 3·NCT04334759·214 enrolled
Gemcitabine as Maintenance Treatment for Diffuse Pleural Mesothelioma
Completed·National Cancer Institute, Egypt·Phase 2·NCT07411144·64 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)